Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Dec 07, 2021 3:45pm
171 Views
Post# 34207736

RE:Large BIOPHARMA 1.7 Trillion in dealmaking firepower.

RE:Large BIOPHARMA 1.7 Trillion in dealmaking firepower.There have been a few multi- billion $ pharma deals lately. Reportedly more to come 2022.
a simple $billion for ONC = about $15 USD/ share.
or in Canadian $ closer to $18ps.
Those who have been around a long time see anything under $25ps++ as less than a good price.
The newbies & recent traders getting all excited over a few dimes, have no idea of Oncs real potential.
And, few would see anything over $5 as amazing!
take a step back _ wider longer view.
The most conservative analysts has projections, of $6ps.
most optimistic being $15ps
All of which are based o; assumptions of getting Pelareorep to market & not a complete take over.
using my nerves of steel, I bought more last week. Averaging down.
The end is near for this very long wait.
byuout, partnership or something elese Will b3 resolved June of 2022 at the latest.
They have $ until early 2023, but need 12 months of operating $ to satisfy listings & regulators.
With A.N. Stating phase 3 to start first 1/2 of 2022. Onc is under both financial & operating pressure to be in the same window.
hence m6 mid year deadline.

<< Previous
Bullboard Posts
Next >>